JP2008540635A - 代謝型グルタミン酸受容体の正のアロステリック調節因子としての置換されたオキシジアゾール誘導体 - Google Patents

代謝型グルタミン酸受容体の正のアロステリック調節因子としての置換されたオキシジアゾール誘導体 Download PDF

Info

Publication number
JP2008540635A
JP2008540635A JP2008511821A JP2008511821A JP2008540635A JP 2008540635 A JP2008540635 A JP 2008540635A JP 2008511821 A JP2008511821 A JP 2008511821A JP 2008511821 A JP2008511821 A JP 2008511821A JP 2008540635 A JP2008540635 A JP 2008540635A
Authority
JP
Japan
Prior art keywords
alkyl
phenyl
oxadiazol
fluoro
methanone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008511821A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008540635A5 (enExample
Inventor
ファリナ，マルコ
ガグリアルディ，ステファニア
ポール，エマニュエル ル
ムテル，バンサン
パロンビ，ジョバンニ
マリア ポリ，ソニア
ロシェル，ジャン−フィリップ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Addex Pharmaceuticals SA
Original Assignee
Addex Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0510138A external-priority patent/GB0510138D0/en
Priority claimed from GBGB0601709.9A external-priority patent/GB0601709D0/en
Application filed by Addex Pharmaceuticals SA filed Critical Addex Pharmaceuticals SA
Publication of JP2008540635A publication Critical patent/JP2008540635A/ja
Publication of JP2008540635A5 publication Critical patent/JP2008540635A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2008511821A 2005-05-18 2006-05-17 代謝型グルタミン酸受容体の正のアロステリック調節因子としての置換されたオキシジアゾール誘導体 Pending JP2008540635A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0510138A GB0510138D0 (en) 2005-05-18 2005-05-18 Novel compounds A4
GBGB0601709.9A GB0601709D0 (en) 2006-01-27 2006-01-27 Novel compounds A4
PCT/IB2006/001881 WO2006123255A2 (en) 2005-05-18 2006-05-17 Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors

Publications (2)

Publication Number Publication Date
JP2008540635A true JP2008540635A (ja) 2008-11-20
JP2008540635A5 JP2008540635A5 (enExample) 2009-07-02

Family

ID=37431638

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008511821A Pending JP2008540635A (ja) 2005-05-18 2006-05-17 代謝型グルタミン酸受容体の正のアロステリック調節因子としての置換されたオキシジアゾール誘導体

Country Status (13)

Country Link
US (1) US20090215822A1 (enExample)
EP (1) EP1893606A2 (enExample)
JP (1) JP2008540635A (enExample)
KR (1) KR20080027463A (enExample)
AU (1) AU2006248655A1 (enExample)
BR (1) BRPI0611423A2 (enExample)
CA (1) CA2608014A1 (enExample)
EA (1) EA015813B1 (enExample)
IL (1) IL187186A0 (enExample)
MX (1) MX2007014444A (enExample)
NO (1) NO20076478L (enExample)
NZ (1) NZ564254A (enExample)
WO (1) WO2006123255A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540637A (ja) * 2005-05-18 2008-11-20 アデックス ファーマ ソシエテ アノニム 陽性の代謝型グルタミン酸受容体アロステリックモジュレーターとしてのピロール誘導体
JP2012524798A (ja) * 2009-04-23 2012-10-18 メルク・シャープ・エンド・ドーム・コーポレイション ２−アルキルピペリジンｍｇｌｕｒ５受容体モジュレーター
WO2016153023A1 (ja) * 2015-03-25 2016-09-29 国立研究開発法人国立長寿医療研究センター 新規オキサジアゾール誘導体及びこれを含有する医薬

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510140D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B2
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
GB0510139D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
GB0622202D0 (en) * 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
SA109300358B1 (ar) 2008-06-06 2012-11-03 استرازينيكا ايه بي مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
TW201035088A (en) 2009-02-27 2010-10-01 Supergen Inc Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
CA2784830C (en) 2009-12-18 2018-03-27 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
EP2632469A2 (en) * 2010-10-25 2013-09-04 Merck Sharp & Dohme Corp. Tricyclic mglur5 receptor modulators
WO2016065584A1 (en) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Piperidine oxadiazole and thiadiazole orexin receptor antagonists
WO2022069953A1 (en) * 2020-09-29 2022-04-07 Ranjith Siddaraj Synthesis and characterization of (s)-3-(5- fluoropyridin-2-yl)-5-(piperidin-3-yl)-l,2,4-oxadiazole derivatives and their secretory phospholipase a2 (spla2) inhibitor activity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014370A2 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Oxadiazoles as modulators of metabotropic glutamate receptor-5
JP2007510713A (ja) * 2003-11-06 2007-04-26 アデックス ファーマシューティカルズ ソシエテ アノニム 代謝型グルタミン酸受容体のアロステリック調節因子
JP2008540637A (ja) * 2005-05-18 2008-11-20 アデックス ファーマ ソシエテ アノニム 陽性の代謝型グルタミン酸受容体アロステリックモジュレーターとしてのピロール誘導体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966748A (en) * 1975-05-08 1976-06-29 American Cyanamid Company Para-fluorophenyl-N-heterocyclic substituted butanes
EP1613615A2 (en) * 2003-04-03 2006-01-11 Merck & Co., Inc. 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5
BRPI0507481A (pt) * 2004-02-18 2007-07-17 Astrazeneca Ab composto, composição farmacêutica, uso do composto, e, métodos para tratar distúrbios mediados por mglur 5 e para inibir ativação de receptores de mglur 5
GB0510143D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
GB0510140D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B2
GB0510139D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
GB0622202D0 (en) * 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014370A2 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Oxadiazoles as modulators of metabotropic glutamate receptor-5
JP2007510713A (ja) * 2003-11-06 2007-04-26 アデックス ファーマシューティカルズ ソシエテ アノニム 代謝型グルタミン酸受容体のアロステリック調節因子
JP2008540637A (ja) * 2005-05-18 2008-11-20 アデックス ファーマ ソシエテ アノニム 陽性の代謝型グルタミン酸受容体アロステリックモジュレーターとしてのピロール誘導体

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540637A (ja) * 2005-05-18 2008-11-20 アデックス ファーマ ソシエテ アノニム 陽性の代謝型グルタミン酸受容体アロステリックモジュレーターとしてのピロール誘導体
JP2012524798A (ja) * 2009-04-23 2012-10-18 メルク・シャープ・エンド・ドーム・コーポレイション ２−アルキルピペリジンｍｇｌｕｒ５受容体モジュレーター
WO2016153023A1 (ja) * 2015-03-25 2016-09-29 国立研究開発法人国立長寿医療研究センター 新規オキサジアゾール誘導体及びこれを含有する医薬

Also Published As

Publication number Publication date
NO20076478L (no) 2008-01-28
NZ564254A (en) 2011-04-29
US20090215822A1 (en) 2009-08-27
WO2006123255A2 (en) 2006-11-23
MX2007014444A (es) 2008-04-21
KR20080027463A (ko) 2008-03-27
IL187186A0 (en) 2008-02-09
AU2006248655A1 (en) 2006-11-23
EA200702469A1 (ru) 2008-06-30
EA015813B1 (ru) 2011-12-30
CA2608014A1 (en) 2006-11-23
WO2006123255A3 (en) 2007-03-29
BRPI0611423A2 (pt) 2010-09-08
EP1893606A2 (en) 2008-03-05

Similar Documents

Publication Publication Date Title
US8030331B2 (en) Allosteric modulators of metabotropic glutamate receptors
US20100004284A1 (en) Novel Heterocyclic Compounds as Positive Allosteric Modulators of Metabotropic Glutamate Receptors
EP1912979B1 (en) Phenyl-{3-(3-(1h-pyrrol-2-yl)-[1,2,4]oxadiazol-5-yl]piperidin-1-yl}-methanone derivatives and related compounds as positive allosteric modulators of metabotropic glutamate receptors
EP2089386B1 (en) Oxazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
JP2008540634A (ja) 新規オキサジアゾール誘導体及び代謝型グルタミン酸受容体の正のアロステリック調節因子としての当該誘導体の使用
JP2008540635A (ja) 代謝型グルタミン酸受容体の正のアロステリック調節因子としての置換されたオキシジアゾール誘導体
US20070299110A1 (en) Novel Tetrazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate
US20090082399A1 (en) Carbamate derivatives as positive allosteric modulators of metabotropic glutamate receptors
CN101228155B (zh) 作为代谢型谷氨酸受体的正变构调节剂的取代的*二唑衍生物
HK1128919B (en) Allosteric modulators of metabotropic glutamate receptors
HK1094204B (en) Allosteric modulators of metabotropic glutamate receptors
HK1112909B (en) Phenyl-{3-(3-(1h-pyrrol-2-yl)-[1,2,4]oxadiazol-5-yl]piperidin-1-yl}-methanone derivatives and related compounds as positive allosteric modulators of metabotropic glutamate receptors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20111221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120319

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120327

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121204